News

An overview of the 7 presentations included as late-breaking clinical trials at ERA 2025.

Sciurba shared his excitement for the recent approval of mepolizumab for people with COPD and an eosinophilic phenotype.

These findings were announced by Sagimet Biosciences, showing that denifanstat met each of its primary and secondary endpoints in patients with acne.

This interview with Steven Daveluy, MD, features a discussion of hidradenitis suppurativa, cutaneous lymphoma, and addressing racial disparities.

A recent study reveals no link between cesarean delivery and childhood allergies, challenging previous findings and highlighting Japan's unique health context.

Hosts discuss a consensus repot from the ADA focused on screening and early interview of MASLD in people with diabetes.

A recent analysis reveals no significant difference between restrictive and liberal transfusion strategies on quality of life in patients with myocardial infarction and anemia.

This prospective observational study suggests that there are differences between the gut microbiome compositions of pediatric patients and others with HS.

Check out these 7 late-breaking abstracts to watch at the upcoming SLEEP 2025 meeting.

New data support the “two-hit” hypothesis: early allergic sensitization plus respiratory infections may impair lung function into adulthood, up to age 25 years.

During his New Wave Dermatology interview, Naveed Sami, MD, spoke about additional takeaways from his session on the cutaneous effects of immunotherapies.

Discover key advancements and setbacks in cardiovascular medicine from May 2025, shaping the future of cardiometabolic care and treatment options.

Investigators examined emergency department utilization as a product of age, patient-reported severity of vaso-occlusive episodes, and Social Vulnerability Index score.

Hosts breakdown diabetes technology updates from May 2025 and Breakthrough T1D's push for improved screening.

In this interview at the New Wave Dermatology meeting, Naveed Sami, MD, highlights some of the notable takeaways from his talk on the impacts of immunotherapies.

This May was characterized by HCPLive’s coverage of the ARVO and Envision conferences, as well as a slew of FDA approvals towards the end of the month.

Lyra Therapeutics announced LYR-210 met primary and secondary endpoints in phase 3 ENLIGHTEN 2, improving CRS symptoms and showing strong safety.

Vera Therapeutics intends to bring the results before the FDA by the end of 2025; they anticipate an approval and commercial launch in 2026.

This Month in Review summary includes a list of some of the most notable or impactful news in the dermatology field from May 2025.

Point-of-care intestinal ultrasound offers real-time, noninvasive monitoring for pediatric IBD, enabling faster, personalized treatment decisions in routine care.

Brendon Neuen, MBBS, PhD, discusses 3 late breaking clinical trials being presented at ERA 2025.

Contrary to prior research, this study indicates that combining tumor necrosis factor inhibitors or another biologic with antimetabolites has a better chance of managing inflammation than any individual medication.

This interview from the 2025 New Wave Dermatology Conference features DiRuggiero discussing challenging psoriasis cases and tips for healthcare providers.

Systematic review of 34 randomized trials finds EMDR most effective, though civilians were more likely than veterans to lose their PTSD diagnosis after treatment.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and new treatment guidelines, in this week's essential news roundup.

A recent study has indicated that FCH results in better tolerability and medication compliance due to lowered risk of adverse gastrointestinal effects.